Amarin Corp Plc (AMRN)

[ggwpq]

Does the inclusion of peripheral artery disease in the NICE Vazkepa a reporting error or fact?

"The just-published final technology appraisal document recommends that Vazkepa (icosapent ethyl) can be prescribed to people in England and Wales for adult patients with high-risk cardiovascular disease and elevated levels of triglycerides (1.7 mmol/litre or above) in their blood who are already taking statins.

That includes people who have suffered a prior stroke or heart attack, or who have other conditions like unstable angina or peripheral artery disease."

https://pharmaphorum.com/news/nice-unlocks-use-of-amarins-vazkepa-in-425k-nhs-patients/